Gujarat Themis Biosyn FY26 Revenue ₹168.25 Cr, PAT ₹46.68 Cr

Gujarat Themis Biosyn Ltd reported FY26 total income of ₹168.25 crores, with EBITDA of ₹75.53 crores and Profit After Tax of ₹46.68 crores. The company significantly expanded its fermentation capacity, more than doubling it, and operationalized a new API facility for both fermentation-based and synthetic APIs. R&D initiatives were advanced, and a hybrid renewable power plant is being established. Key strategic moves include the acquisition of 13 global brands from Sanofi across anti-TB and anti-infective portfolios, granting access to over 55 countries. Additionally, a wholly owned subsidiary, Themis Biosyn Japan Limited, was incorporated, acquiring Japan-based MicroBiopharm Japan Co. Ltd. specializing in precision fermentation.